Inhibikase Therapeutics Files 2025 Proxy Statement
Ticker: IKT · Form: DEF 14A · Filed: May 12, 2025 · CIK: 1750149
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
Related Tickers: IKT
TL;DR
IKT proxy statement filed, shareholders vote June 27.
AI Summary
Inhibikase Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on May 12, 2025, for its annual meeting on June 27, 2025. The filing concerns the solicitation of proxies from shareholders regarding matters to be voted on at the meeting. The company is based in Atlanta, GA, and operates in the biological products sector.
Why It Matters
This filing provides shareholders with crucial information about the company's governance and upcoming votes, impacting their ability to make informed decisions about their investment.
Risk Assessment
Risk Level: low — This is a routine annual filing and does not contain new material financial or operational information that would inherently increase risk.
Key Numbers
- 20250627 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
- 20250512 — Filing Date (Date the proxy statement was submitted to the SEC.)
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- 0000950170-25-069152 (filing_id) — Accession Number
- 20250512 (date) — Filing Date
- 20250627 (date) — Meeting Date
- Atlanta, GA (location) — Company Headquarters
FAQ
What is the purpose of this DEF 14A filing?
The purpose is to solicit proxies from shareholders for the annual meeting of Inhibikase Therapeutics, Inc. to be held on June 27, 2025.
When was the definitive proxy statement filed?
The definitive proxy statement was filed on May 12, 2025.
What is the company's name and ticker symbol?
The company's name is Inhibikase Therapeutics, Inc. The ticker symbol is not explicitly stated in this excerpt but can be inferred from the context of SEC filings.
Where is Inhibikase Therapeutics, Inc. located?
The company's business and mailing address is 3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA 30339.
What is the fiscal year end for Inhibikase Therapeutics, Inc.?
The fiscal year end for Inhibikase Therapeutics, Inc. is December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 12, 2025 regarding Inhibikase Therapeutics, Inc. (IKT).